logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • U.S. Pharmaceuticals drugs

    FiltersReset Filters
    16 results

    • bosulif

      (Bosutinib)
      U.S. Pharmaceuticals
      Usage: BOSULIF is indicated for treating adults and pediatric patients (1 year and older) with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), as well as adults with accelerated or blast phase Ph+ CML who are resistant or intolerant to prior therapies.

    • caverject impulse

      (Alprostadil)
      U.S. Pharmaceuticals
      Usage: CAVERJECT IMPULSE is indicated for treating erectile dysfunction and as an adjunct to other diagnostic tests for diagnosing erectile dysfunction.

    • cibinqo

      (abrocitinib)
      U.S. Pharmaceuticals
      Usage: CIBINQO is indicated for treating refractory, moderate-to-severe atopic dermatitis in adults and patients aged 12 and older, when the condition is not adequately managed by other systemic therapies or when those treatments are unsuitable. Co-use with other JAK inhibitors or biologics is not recommended.

    • duavee

      (conjugated estrogens/bazedoxifene)
      U.S. Pharmaceuticals
      Usage: DUAVEE is indicated for women with a uterus to treat moderate to severe vasomotor symptoms related to menopause and to prevent postmenopausal osteoporosis. It should be used for the shortest duration necessary, with periodic re-evaluation of treatment needs.

    • elrexfio

      (elranatamab-bcmm)
      U.S. Pharmaceuticals
      Usage: ELREXFIO is indicated for treating adult patients with relapsed or refractory multiple myeloma who have undergone at least four prior therapy lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Continued approval may depend on further clinical evidence.

    • ibrance

      (palbociclib)
      U.S. Pharmaceuticals
      Usage: IBRANCE is indicated for adult patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, used in combination with an aromatase inhibitor as initial therapy or fulvestrant after disease progression following endocrine therapy.

    • ibrance

      (palbociclib)
      U.S. Pharmaceuticals
      Usage: IBRANCE is indicated for treating adult patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, either in combination with an aromatase inhibitor as initial endocrine therapy or with fulvestrant for those with disease progression after endocrine therapy.

    • inlyta

      (axitinib)
      U.S. Pharmaceuticals
      Usage: INLYTA is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in combination with avelumab or pembrolizumab. It is also indicated as a single agent for advanced RCC following the failure of one prior systemic therapy.

    • litfulo

      (ritlecitinib)
      U.S. Pharmaceuticals
      Usage: LITFULO is indicated for treating severe alopecia areata in adults and adolescents aged 12 and older. It should not be used with other JAK inhibitors, biologic immunomodulators, cyclosporine, or potent immunosuppressants.

    • lorbrena

      (lorlatinib)
      U.S. Pharmaceuticals
      Usage: LORBRENA® is indicated for treating adult patients with metastatic non-small cell lung cancer (NSCLC) who have ALK-positive tumors, as confirmed by an FDA-approved test.